这是一篇来自已证抗体库的有关人类 SPARC的综述,是根据26篇发表使用所有方法的文章归纳的。这综述旨在帮助来邦网的访客找到最适合SPARC 抗体。
SPARC 同义词: BM-40; OI17; ON; ONT

赛默飞世尔
小鼠 单克隆(ON1-1)
  • 免疫组化; 犬; 图 6
赛默飞世尔 SPARC抗体(Zymed, 33-5500)被用于被用于免疫组化在犬样本上 (图 6). Biotech Histochem (2016) ncbi
小鼠 单克隆(ON1-1)
  • 免疫细胞化学; 人类; 图 1
赛默飞世尔 SPARC抗体(Zymed, 33-5500)被用于被用于免疫细胞化学在人类样本上 (图 1). Arch Oral Biol (2016) ncbi
小鼠 单克隆(ON1-1)
  • 酶联免疫吸附测定; 人类
赛默飞世尔 SPARC抗体(Invitrogen, 33-5500)被用于被用于酶联免疫吸附测定在人类样本上. PLoS ONE (2015) ncbi
小鼠 单克隆(ON1-1)
  • 免疫组化; 人类; 1:400; 图 1
赛默飞世尔 SPARC抗体(Invitrogen, 33-5500)被用于被用于免疫组化在人类样本上浓度为1:400 (图 1). Clin Lung Cancer (2015) ncbi
小鼠 单克隆(ON1-1)
  • 免疫组化; 犬; 图 5
赛默飞世尔 SPARC抗体(Zymed, 33-5500)被用于被用于免疫组化在犬样本上 (图 5). Biotech Histochem (2015) ncbi
小鼠 单克隆(ON1-1)
  • 免疫组化; 人类; 1:100
赛默飞世尔 SPARC抗体(Invitrogen, 33-5500)被用于被用于免疫组化在人类样本上浓度为1:100. Hum Pathol (2014) ncbi
小鼠 单克隆(ON1-1)
  • 酶联免疫吸附测定; 人类; 图 1
赛默飞世尔 SPARC抗体(生活技术, ON1-1)被用于被用于酶联免疫吸附测定在人类样本上 (图 1). PLoS ONE (2013) ncbi
小鼠 单克隆(ON1-1)
  • 免疫组化; 人类; 1:1000; 图 3
赛默飞世尔 SPARC抗体(Invitrogen, 33-5500)被用于被用于免疫组化在人类样本上浓度为1:1000 (图 3). Clin Cancer Res (2013) ncbi
小鼠 单克隆(ON1-1)
  • 免疫组化-石蜡切片; 人类; 10 ug/ml; 图 2
赛默飞世尔 SPARC抗体(ZYMED, clone ON1-1)被用于被用于免疫组化-石蜡切片在人类样本上浓度为10 ug/ml (图 2). PLoS ONE (2013) ncbi
小鼠 单克隆(ON1-1)
  • 免疫组化; 大鼠; 图 5
赛默飞世尔 SPARC抗体(Zymed, 33-5500)被用于被用于免疫组化在大鼠样本上 (图 5). Am J Orthod Dentofacial Orthop (2011) ncbi
小鼠 单克隆(ON1-1)
  • 免疫组化-石蜡切片; 人类; 1:6000; 图 1
赛默飞世尔 SPARC抗体(Zymed, ON1-1)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:6000 (图 1). APMIS (2009) ncbi
小鼠 单克隆(ON1-1)
  • 免疫组化; 人类
赛默飞世尔 SPARC抗体(Zymed, ON1-1)被用于被用于免疫组化在人类样本上. Am J Pathol (2009) ncbi
小鼠 单克隆(ON1-1)
  • 免疫组化-石蜡切片; 人类; 1:500
赛默飞世尔 SPARC抗体(Zymed Laboratories, ON1-1)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:500. Mod Pathol (2008) ncbi
小鼠 单克隆(ON1-1)
  • 免疫细胞化学; 人类; 5 ug/ml; 图 3
  • 免疫印迹; 人类; 图 2
赛默飞世尔 SPARC抗体(Zymed, 33-5500)被用于被用于免疫细胞化学在人类样本上浓度为5 ug/ml (图 3) 和 被用于免疫印迹在人类样本上 (图 2). Exp Biol Med (Maywood) (2008) ncbi
小鼠 单克隆(ON1-1)
  • 免疫组化-石蜡切片; 人类
赛默飞世尔 SPARC抗体(Zymed, ON1-1)被用于被用于免疫组化-石蜡切片在人类样本上. J Clin Oncol (2007) ncbi
小鼠 单克隆(ON1-1)
  • 免疫组化; 人类; 1:200; 图 8B
  • 免疫印迹; 人类; 1:1000
赛默飞世尔 SPARC抗体(Zymed, ON1-1)被用于被用于免疫组化在人类样本上浓度为1:200 (图 8B) 和 被用于免疫印迹在人类样本上浓度为1:1000. Int J Cancer (2006) ncbi
小鼠 单克隆(ON1-1)
  • 免疫组化; 人类; 图 2
赛默飞世尔 SPARC抗体(Zymed, ON1-1)被用于被用于免疫组化在人类样本上 (图 2). Oncogene (2003) ncbi
安迪生物R&D
domestic goat 多克隆
  • 免疫组化; 小鼠; 图 5e
安迪生物R&D SPARC抗体(R&D Systems, AF941)被用于被用于免疫组化在小鼠样本上 (图 5e). Oncotarget (2016) ncbi
domestic goat 多克隆
安迪生物R&D SPARC抗体(R&D Systems, AF941)被用于. PLoS ONE (2015) ncbi
艾博抗(上海)贸易有限公司
domestic rabbit 多克隆
  • 免疫印迹; 大鼠; 1:500; 图 2b
艾博抗(上海)贸易有限公司 SPARC抗体(Abcam, ab55847)被用于被用于免疫印迹在大鼠样本上浓度为1:500 (图 2b). Biosci Rep (2019) ncbi
赛信通(上海)生物试剂有限公司
domestic rabbit 多克隆
  • 免疫印迹; 人类; 图 1a
赛信通(上海)生物试剂有限公司 SPARC抗体(CST, 5420)被用于被用于免疫印迹在人类样本上 (图 1a). Cell Commun Signal (2019) ncbi
domestic rabbit 单克隆(D10F10)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司 SPARC抗体(Cell Signaling Technology, D10F10)被用于被用于免疫印迹在人类样本上. PLoS Pathog (2014) ncbi
徕卡显微系统(上海)贸易有限公司
(15G12)
  • proximity ligation assay; 人类; 1:50; 图 4
徕卡显微系统(上海)贸易有限公司 SPARC抗体(Novocastra, ncl-o-nectin)被用于被用于proximity ligation assay在人类样本上浓度为1:50 (图 4). Am J Pathol (2017) ncbi
(15G12)
  • 免疫细胞化学; 人类; 图 4c
徕卡显微系统(上海)贸易有限公司 SPARC抗体(Novocastra, 15G12)被用于被用于免疫细胞化学在人类样本上 (图 4c). Folia Biol (Praha) (2016) ncbi
(15G12)
  • 免疫组化-石蜡切片; 人类; 1:80; 图 1d
徕卡显微系统(上海)贸易有限公司 SPARC抗体(Novocastra, 15G12)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:80 (图 1d). J Pathol (2016) ncbi
Developmental Studies Hybridoma Bank
小鼠 单克隆(AON-1)
  • 免疫细胞化学; 人类; 1:5
Developmental Studies Hybridoma Bank SPARC抗体(DSHB, AON-1)被用于被用于免疫细胞化学在人类样本上浓度为1:5. Anticancer Res (2004) ncbi
文章列表
  1. Wang Q, Yang Q, Zhang A, Kang Z, Wang Y, Zhang Z. Silencing of SPARC represses heterotopic ossification via inhibition of the MAPK signaling pathway. Biosci Rep. 2019;39: pubmed 出版商
  2. Jiang S, Zhang M, Zhang Y, Zhou W, Zhu T, Ruan Q, et al. WNT5B governs the phenotype of basal-like breast cancer by activating WNT signaling. Cell Commun Signal. 2019;17:109 pubmed 出版商
  3. Jørgensen L, Jepsen P, Boysen A, Dalgaard L, Hvid L, Ørtenblad N, et al. SPARC Interacts with Actin in Skeletal Muscle in Vitro and in Vivo. Am J Pathol. 2017;187:457-474 pubmed 出版商
  4. Ozdal Kurt F, Tuglu I, Vatansever H, Tong S, Sen B, Deliloglu Gurhan S. The effect of different implant biomaterials on the behavior of canine bone marrow stromal cells during their differentiation into osteoblasts. Biotech Histochem. 2016;91:412-22 pubmed 出版商
  5. Ozdal Kurt F, Sen B, Tuglu I, Vatansever S, Türk B, Deliloglu Gurhan I. Attachment and growth of dental pulp stem cells on dentin in presence of extra calcium. Arch Oral Biol. 2016;68:131-41 pubmed 出版商
  6. Riabov V, Yin S, Song B, Avdic A, Schledzewski K, Ovsiy I, et al. Stabilin-1 is expressed in human breast cancer and supports tumor growth in mammary adenocarcinoma mouse model. Oncotarget. 2016;7:31097-110 pubmed 出版商
  7. Suchanek J, Suchánková Kleplová T, Rehacek V, Browne K, Soukup T. Proliferative Capacity and Phenotypical Alteration of Multipotent Ecto-Mesenchymal Stem Cells from Human Exfoliated Deciduous Teeth Cultured in Xenogeneic and Allogeneic Media. Folia Biol (Praha). 2016;62:1-14 pubmed
  8. McCart Reed A, Kutasovic J, Vargas A, Jayanthan J, Al Murrani A, Reid L, et al. An epithelial to mesenchymal transition programme does not usually drive the phenotype of invasive lobular carcinomas. J Pathol. 2016;238:489-94 pubmed 出版商
  9. Jokerst J, Chen Z, Xu L, Nolley R, Chang E, Mitchell B, et al. A Magnetic Bead-Based Sensor for the Quantification of Multiple Prostate Cancer Biomarkers. PLoS ONE. 2015;10:e0139484 pubmed 出版商
  10. Riordan D, Varma S, West R, Brown P. Automated Analysis and Classification of Histological Tissue Features by Multi-Dimensional Microscopic Molecular Profiling. PLoS ONE. 2015;10:e0128975 pubmed 出版商
  11. Bertino E, Williams T, Nana Sinkam S, Shilo K, Chatterjee M, Mo X, et al. Stromal Caveolin-1 Is Associated With Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients. Clin Lung Cancer. 2015;16:466-74 pubmed 出版商
  12. Özdal Kurt F, TuÄŸlu I, Vatansever H, Tong S, DeliloÄŸlu Gürhan S. The effect of autologous bone marrow stromal cells differentiated on scaffolds for canine tibial bone reconstruction. Biotech Histochem. 2015;90:516-28 pubmed 出版商
  13. Ren K, Yao N, Wang G, Tian L, Ma J, Shi X, et al. Vasculogenic mimicry: a new prognostic sign of human osteosarcoma. Hum Pathol. 2014;45:2120-9 pubmed 出版商
  14. Chattergoon M, Latanich R, Quinn J, Winter M, Buckheit R, Blankson J, et al. HIV and HCV activate the inflammasome in monocytes and macrophages via endosomal Toll-like receptors without induction of type 1 interferon. PLoS Pathog. 2014;10:e1004082 pubmed 出版商
  15. Xu L, Ping F, Yin J, Xiao X, Xiang H, Ballantyne C, et al. Elevated plasma SPARC levels are associated with insulin resistance, dyslipidemia, and inflammation in gestational diabetes mellitus. PLoS ONE. 2013;8:e81615 pubmed 出版商
  16. Chen J, Espinosa I, Lin A, Liao O, van de Rijn M, West R. Stromal responses among common carcinomas correlated with clinicopathologic features. Clin Cancer Res. 2013;19:5127-35 pubmed 出版商
  17. Triulzi T, Casalini P, Sandri M, Ratti M, Carcangiu M, Colombo M, et al. Neoplastic and stromal cells contribute to an extracellular matrix gene expression profile defining a breast cancer subtype likely to progress. PLoS ONE. 2013;8:e56761 pubmed 出版商
  18. Ozturk F, Babacan H, Inan S, Gumus C. Effects of bisphosphonates on sutural bone formation and relapse: A histologic and immunohistochemical study. Am J Orthod Dentofacial Orthop. 2011;140:e31-41 pubmed 出版商
  19. Daugaard S, Christensen L, Høgdall E. Markers aiding the diagnosis of chondroid tumors: an immunohistochemical study including osteonectin, bcl-2, cox-2, actin, calponin, D2-40 (podoplanin), mdm-2, CD117 (c-kit), and YKL-40. APMIS. 2009;117:518-25 pubmed 出版商
  20. Andersen T, Sondergaard T, Skorzynska K, Dagnaes Hansen F, Plesner T, Hauge E, et al. A physical mechanism for coupling bone resorption and formation in adult human bone. Am J Pathol. 2009;174:239-47 pubmed 出版商
  21. Hong S, Kelly D, Griffith M, Omura N, Li A, Li C, et al. Multiple genes are hypermethylated in intraductal papillary mucinous neoplasms of the pancreas. Mod Pathol. 2008;21:1499-507 pubmed 出版商
  22. Pan M, Chang H, Chuang L, Hung W. The nonsteroidal anti-inflammatory drug NS398 reactivates SPARC expression via promoter demethylation to attenuate invasiveness of lung cancer cells. Exp Biol Med (Maywood). 2008;233:456-62 pubmed 出版商
  23. Infante J, Matsubayashi H, Sato N, Tonascia J, Klein A, Riall T, et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol. 2007;25:319-25 pubmed
  24. Chlenski A, Liu S, Guerrero L, Yang Q, Tian Y, Salwen H, et al. SPARC expression is associated with impaired tumor growth, inhibited angiogenesis and changes in the extracellular matrix. Int J Cancer. 2006;118:310-6 pubmed
  25. Pautke C, Schieker M, Tischer T, Kolk A, Neth P, Mutschler W, et al. Characterization of osteosarcoma cell lines MG-63, Saos-2 and U-2 OS in comparison to human osteoblasts. Anticancer Res. 2004;24:3743-8 pubmed
  26. Sato N, Fukushima N, Maehara N, Matsubayashi H, Koopmann J, Su G, et al. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene. 2003;22:5021-30 pubmed